Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients

被引:79
|
作者
Burkhardt, Christian [1 ]
Neuwirth, Christoph [1 ]
Sommacal, Andreas [2 ]
Andersen, Peter M. [3 ]
Weber, Markus [1 ]
机构
[1] Kantonsspital St Gallen, Neuromuscular Dis Unit, ALS Clin, St Gallen, Switzerland
[2] Kantonsspital St Gallen, Dept Pathol, St Gallen, Switzerland
[3] Umea Univ, Inst Pharmacol & Clin Neurosci, Umea, Sweden
来源
PLOS ONE | 2017年 / 12卷 / 05期
基金
瑞士国家科学基金会;
关键词
QUALITY STANDARDS SUBCOMMITTEE; NONINVASIVE VENTILATION; RESPIRATORY-FAILURE; PRACTICE PARAMETER; AMERICAN ACADEMY; FRENCH PATIENTS; DEATH; CARE; DIAGNOSIS; CRITERIA;
D O I
10.1371/journal.pone.0177555
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Non-invasive ventilation (NIV) and percutaneous gastrostomy (PEG) are guideline-recommended interventions for symptom management in amyotrophic lateral sclerosis (ALS). Their effect on survival is controversial and the impact on causes of death is unknown. Objective To investigate the effect of NIV and PEG on survival and causes of death in ALS patients. Methods Eighty deceased ALS patients underwent a complete post mortem analysis for causes of death between 2003 and 2015. Forty-two of these patients consented for genetic testing. Effects of NIV and PEG on survival and causes of death were analyzed in a multivariable Cox proportional hazard regression. Results Six patients, who requested assisted suicide causing drug-induced hypoxia, were excluded from final analysis. Respiratory failure was the main cause of death in 72 out of 74 patients. Fifteen out of 74 died of aspiration pneumonia 23/74 of bronchopneumonia and 8/74 of a combination of aspiration pneumonia and bronchopneumonia. Twenty died of hypoxia without concomitant infection, and six patients had pulmonary embolism alone or in combination with pneumonia. NIV (p = 0.01) and PEG (p<0.01) had a significant impact on survival. In patients using NIV bronchopneumonia was significantly more frequent (p <0.04) compared to non-NIV patients. This effect was even more pronounced in limb onset patients (p<0.002). Patients with C9orf72 hexanucleotide repeat expansions showed faster disease progression and shorter survival (p = 0.01). Conclusion The use of NIV and PEG prolongs survival in ALS. This study supports current AAN and EFNS guidelines which recommend NIV and PEG as a treatment option in ALS. The risk of bronchopneumonia as cause of death may be increased by NIV.
引用
收藏
页数:12
相关论文
共 39 条
  • [31] Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort study
    Federica Edith Pisa
    Giancarlo Logroscino
    Paolo Giacomelli Battiston
    Fabio Barbone
    BMC Pulmonary Medicine, 16
  • [32] Elevated serum ferritin level as a predictor of reduced survival in patients with sporadic amyotrophic lateral sclerosis in China: a retrospective study
    Sun, Qionghua
    Yang, Fei
    Wang, Hongfen
    Cui, Fang
    Li, Yanran
    Li, Siyuan
    Ren, Yuting
    Lan, Wenjie
    Li, Mao
    Zhu, Wenjia
    Sun, Xiaosun
    He, Zhengqing
    Zhao, Xue
    Yang, Li
    Huang, Xusheng
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2019, 20 (3-4) : 186 - 191
  • [33] Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS)
    Edgar, Suzanna
    Ellis, Melina
    Abdul-Aziz, Nur Adilah
    Goh, Khean-Jin
    Shahrizaila, Nortina
    Kennerson, Marina L.
    Ahmad-Annuar, Azlina
    NEUROBIOLOGY OF AGING, 2021, 108 : 200 - 206
  • [34] Survival of amyotrophic lateral sclerosis patients after admission to the intensive care unit for acute respiratory failure: an observational cohort study
    Mayaux, Julien
    Lambert, Jerome
    Morelot-Panzini, Capucine
    Gonzalez-Bermejo, Jesus
    Delemazure, Julie
    Llontop, Claudia
    Bruneteau, Gaelle
    Salachas, Francois
    Dres, Martin
    Demoule, Alexandre
    Similowski, Thomas
    JOURNAL OF CRITICAL CARE, 2019, 50 : 54 - 58
  • [35] Association Between Serum Lipids and Survival in Patients With Amyotrophic Lateral Sclerosis A Meta-analysis and Population-Based Study
    van Mantgem, Mark Janse R.
    van Rheenen, Wouter
    Hackeng, Anemone V.
    van Es, Michael A.
    Veldink, Jan H.
    van den Berg, Leonard H.
    van Eijk, Ruben P. A.
    NEUROLOGY, 2023, 100 (10) : E1062 - E1071
  • [36] Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
    Vucic, Steve
    Kiernan, Matthew C.
    Menon, Parvathi
    Huynh, William
    Rynders, Austin
    Ho, Karen S.
    Glanzman, Robert
    Hotchkin, Michael T.
    BMJ OPEN, 2021, 11 (01): : e041479
  • [37] Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension
    Vucic, Steve
    Menon, Parvathi
    Huynh, William
    Mahoney, Colin
    Ho, Karen S.
    Hartford, Alan
    Rynders, Austin
    Evan, Jacob
    Evan, Jeremy
    Ligozio, Shelia
    Glanzman, Robert
    Hotchkin, Michael T.
    Kiernan, Matthew C.
    ECLINICALMEDICINE, 2023, 60
  • [38] The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
    Collins, Mahlon
    Riascos, David
    Kovalik, Tina
    An, Jiyan
    Krupa, Kelly
    Krupa, Kristin
    Hood, Brian L.
    Conrads, Thomas P.
    Renton, Alan E.
    Traynor, Bryan J.
    Bowser, Robert
    ACTA NEUROPATHOLOGICA, 2012, 124 (05) : 717 - 732
  • [39] Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study
    Bech, Anne Berit
    Clausen, Thomas
    Waal, Helge
    Delaveris, Gerd Jorunn Moller
    Skeie, Ivar
    ADDICTION, 2022, 117 (04) : 977 - 985